Ruijin Hospital, a tertiary hospital in Shanghai, and Suzhou Abogen Biosciences (AbogenBio), a company dedicated to messenger ribonucleic acid (mRNA) drug discovery, development and commercialization, jointly inaugurated a research institute in SIP recently.

The research institute aims to make full use of AbogenBio’s mRNA drug discovery capability and Ruijin Hospital’s innovation chain covering clinical and laboratory studies to explore possibilities of using mRNA drugs to treat tumors and autoimmune diseases.

November 29, 2024